Loading…
Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients
Aims Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile. Methods and Results During a 6‐year period, four hospitals submitted 735 stool specimens from...
Saved in:
Published in: | Journal of applied microbiology 2018-11, Vol.125 (5), p.1518-1525 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233 |
---|---|
cites | cdi_FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233 |
container_end_page | 1525 |
container_issue | 5 |
container_start_page | 1518 |
container_title | Journal of applied microbiology |
container_volume | 125 |
creator | Baghani, A. Ghourchian, S. Aliramezani, A. Yaseri, M. Mesdaghinia, A. Douraghi, M. |
description | Aims
Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile.
Methods and Results
During a 6‐year period, four hospitals submitted 735 stool specimens from patients suspected for C. difficile infections to the anaerobic bacteriology laboratory. The 46 C. difficile isolates were subjected to disc diffusion and minimum inhibitory concentration (MIC) Test Strips. All isolates were susceptible to vancomycin (VAN) while the highly resistant phenotypes of metronidazole (MTZ) (67·4%), moxifloxacin (78·3%), ciprofloxacin (69·5%) and tetracycline (82·6%) were observed. Of more concern, 67·3% of C. difficile isolates displayed multidrug‐resistant phenotypes. More than half of the isolates (n = 27, 58·6%) were coresistant to ciprofloxacin and moxifloxacin. The MIC90 of VAN was ≤2 mg l−1, whereas this value for MTZ, ciprofloxacin, moxifloxacin and tetracycline was higher than the resistance breakpoints. According to the comparison of interpretive categories for two tests, the categorical agreement was less than 90% for VAN, ciprofloxacin and tetracycline.
Conclusions
The disc diffusion method can be used to detect the isolates with reduced susceptibility to MTZ or moxifloxacin. The high rate of resistance to fluoroquinolones highlights the possibility of the emergence of hypervirulent strains in our settings.
Significance and Impact of the Study
This study provides data regarding the high level of resistance against multiple antibiotics except VAN. |
doi_str_mv | 10.1111/jam.14035 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2062834056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2120019052</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233</originalsourceid><addsrcrecordid>eNp1kM1KAzEURoMotlYXvoAMuNHFtPmd6SxLUVupCKLrkGYSTZmZ1CSDdOcj-Iw-ibFTXQhmkVwuh48vB4BTBIcontFK1ENEIWF7oI9IxlKc5Xh_O9OUwRz3wJH3KwgRgSw7BD1cFCwfF6QPHmbm-aXaJKIJZmlsMPLz_cMpb3yIq2RaWR-cKU1bJ6XR2khTqcR4W4mgfKKdrZO5E40RTbIWwagm-GNwoEXl1cnuHYCn66vH6Sxd3N_Mp5NFKgkjLFWZgnTMCEWxiaJSFFjAEhO01EUGBcVCMCzzjGo81iInhYS51CwSpGQy3gNw0eWunX1tlQ-8Nl6qqhKNsq3nGGZ4TGj8cUTP_6Ar27omtuMY4eilgAxH6rKjpLPeO6X52plauA1HkH-L5lE034qO7NkusV3Wqvwlf8xGYNQBb9HY5v8kfju56yK_AAihh6k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2120019052</pqid></control><display><type>article</type><title>Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients</title><source>Alma/SFX Local Collection</source><creator>Baghani, A. ; Ghourchian, S. ; Aliramezani, A. ; Yaseri, M. ; Mesdaghinia, A. ; Douraghi, M.</creator><creatorcontrib>Baghani, A. ; Ghourchian, S. ; Aliramezani, A. ; Yaseri, M. ; Mesdaghinia, A. ; Douraghi, M.</creatorcontrib><description>Aims
Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile.
Methods and Results
During a 6‐year period, four hospitals submitted 735 stool specimens from patients suspected for C. difficile infections to the anaerobic bacteriology laboratory. The 46 C. difficile isolates were subjected to disc diffusion and minimum inhibitory concentration (MIC) Test Strips. All isolates were susceptible to vancomycin (VAN) while the highly resistant phenotypes of metronidazole (MTZ) (67·4%), moxifloxacin (78·3%), ciprofloxacin (69·5%) and tetracycline (82·6%) were observed. Of more concern, 67·3% of C. difficile isolates displayed multidrug‐resistant phenotypes. More than half of the isolates (n = 27, 58·6%) were coresistant to ciprofloxacin and moxifloxacin. The MIC90 of VAN was ≤2 mg l−1, whereas this value for MTZ, ciprofloxacin, moxifloxacin and tetracycline was higher than the resistance breakpoints. According to the comparison of interpretive categories for two tests, the categorical agreement was less than 90% for VAN, ciprofloxacin and tetracycline.
Conclusions
The disc diffusion method can be used to detect the isolates with reduced susceptibility to MTZ or moxifloxacin. The high rate of resistance to fluoroquinolones highlights the possibility of the emergence of hypervirulent strains in our settings.
Significance and Impact of the Study
This study provides data regarding the high level of resistance against multiple antibiotics except VAN.</description><identifier>ISSN: 1364-5072</identifier><identifier>EISSN: 1365-2672</identifier><identifier>DOI: 10.1111/jam.14035</identifier><identifier>PMID: 29957893</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Anti-Infective Agents - pharmacology ; Antibiotic resistance ; antibiotic susceptibility testing ; Antibiotics ; Bacteria ; Bacteriology ; Breakpoints ; Ciprofloxacin ; Ciprofloxacin - pharmacology ; Clostridium difficile ; Clostridium difficile - drug effects ; Clostridium difficile - isolation & purification ; Clostridium difficile - pathogenicity ; Clostridium Infections - drug therapy ; Clostridium Infections - microbiology ; disc diffusion ; Drug Resistance, Multiple, Bacterial ; Fluoroquinolones ; Fluoroquinolones - pharmacology ; Humans ; Iran ; Metronidazole ; Metronidazole - pharmacology ; MIC Test Strips ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Moxifloxacin ; Patients ; Phenotypes ; resistance ; Vancomycin ; Vancomycin - pharmacology</subject><ispartof>Journal of applied microbiology, 2018-11, Vol.125 (5), p.1518-1525</ispartof><rights>2018 The Society for Applied Microbiology</rights><rights>2018 The Society for Applied Microbiology.</rights><rights>Copyright © 2018 The Society for Applied Microbiology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233</citedby><cites>FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233</cites><orcidid>0000-0001-5861-3182</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29957893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baghani, A.</creatorcontrib><creatorcontrib>Ghourchian, S.</creatorcontrib><creatorcontrib>Aliramezani, A.</creatorcontrib><creatorcontrib>Yaseri, M.</creatorcontrib><creatorcontrib>Mesdaghinia, A.</creatorcontrib><creatorcontrib>Douraghi, M.</creatorcontrib><title>Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients</title><title>Journal of applied microbiology</title><addtitle>J Appl Microbiol</addtitle><description>Aims
Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile.
Methods and Results
During a 6‐year period, four hospitals submitted 735 stool specimens from patients suspected for C. difficile infections to the anaerobic bacteriology laboratory. The 46 C. difficile isolates were subjected to disc diffusion and minimum inhibitory concentration (MIC) Test Strips. All isolates were susceptible to vancomycin (VAN) while the highly resistant phenotypes of metronidazole (MTZ) (67·4%), moxifloxacin (78·3%), ciprofloxacin (69·5%) and tetracycline (82·6%) were observed. Of more concern, 67·3% of C. difficile isolates displayed multidrug‐resistant phenotypes. More than half of the isolates (n = 27, 58·6%) were coresistant to ciprofloxacin and moxifloxacin. The MIC90 of VAN was ≤2 mg l−1, whereas this value for MTZ, ciprofloxacin, moxifloxacin and tetracycline was higher than the resistance breakpoints. According to the comparison of interpretive categories for two tests, the categorical agreement was less than 90% for VAN, ciprofloxacin and tetracycline.
Conclusions
The disc diffusion method can be used to detect the isolates with reduced susceptibility to MTZ or moxifloxacin. The high rate of resistance to fluoroquinolones highlights the possibility of the emergence of hypervirulent strains in our settings.
Significance and Impact of the Study
This study provides data regarding the high level of resistance against multiple antibiotics except VAN.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Infective Agents - pharmacology</subject><subject>Antibiotic resistance</subject><subject>antibiotic susceptibility testing</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Bacteriology</subject><subject>Breakpoints</subject><subject>Ciprofloxacin</subject><subject>Ciprofloxacin - pharmacology</subject><subject>Clostridium difficile</subject><subject>Clostridium difficile - drug effects</subject><subject>Clostridium difficile - isolation & purification</subject><subject>Clostridium difficile - pathogenicity</subject><subject>Clostridium Infections - drug therapy</subject><subject>Clostridium Infections - microbiology</subject><subject>disc diffusion</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Fluoroquinolones</subject><subject>Fluoroquinolones - pharmacology</subject><subject>Humans</subject><subject>Iran</subject><subject>Metronidazole</subject><subject>Metronidazole - pharmacology</subject><subject>MIC Test Strips</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Moxifloxacin</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>resistance</subject><subject>Vancomycin</subject><subject>Vancomycin - pharmacology</subject><issn>1364-5072</issn><issn>1365-2672</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kM1KAzEURoMotlYXvoAMuNHFtPmd6SxLUVupCKLrkGYSTZmZ1CSDdOcj-Iw-ibFTXQhmkVwuh48vB4BTBIcontFK1ENEIWF7oI9IxlKc5Xh_O9OUwRz3wJH3KwgRgSw7BD1cFCwfF6QPHmbm-aXaJKIJZmlsMPLz_cMpb3yIq2RaWR-cKU1bJ6XR2khTqcR4W4mgfKKdrZO5E40RTbIWwagm-GNwoEXl1cnuHYCn66vH6Sxd3N_Mp5NFKgkjLFWZgnTMCEWxiaJSFFjAEhO01EUGBcVCMCzzjGo81iInhYS51CwSpGQy3gNw0eWunX1tlQ-8Nl6qqhKNsq3nGGZ4TGj8cUTP_6Ar27omtuMY4eilgAxH6rKjpLPeO6X52plauA1HkH-L5lE034qO7NkusV3Wqvwlf8xGYNQBb9HY5v8kfju56yK_AAihh6k</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Baghani, A.</creator><creator>Ghourchian, S.</creator><creator>Aliramezani, A.</creator><creator>Yaseri, M.</creator><creator>Mesdaghinia, A.</creator><creator>Douraghi, M.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TM</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5861-3182</orcidid></search><sort><creationdate>201811</creationdate><title>Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients</title><author>Baghani, A. ; Ghourchian, S. ; Aliramezani, A. ; Yaseri, M. ; Mesdaghinia, A. ; Douraghi, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Infective Agents - pharmacology</topic><topic>Antibiotic resistance</topic><topic>antibiotic susceptibility testing</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Bacteriology</topic><topic>Breakpoints</topic><topic>Ciprofloxacin</topic><topic>Ciprofloxacin - pharmacology</topic><topic>Clostridium difficile</topic><topic>Clostridium difficile - drug effects</topic><topic>Clostridium difficile - isolation & purification</topic><topic>Clostridium difficile - pathogenicity</topic><topic>Clostridium Infections - drug therapy</topic><topic>Clostridium Infections - microbiology</topic><topic>disc diffusion</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Fluoroquinolones</topic><topic>Fluoroquinolones - pharmacology</topic><topic>Humans</topic><topic>Iran</topic><topic>Metronidazole</topic><topic>Metronidazole - pharmacology</topic><topic>MIC Test Strips</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Moxifloxacin</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>resistance</topic><topic>Vancomycin</topic><topic>Vancomycin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baghani, A.</creatorcontrib><creatorcontrib>Ghourchian, S.</creatorcontrib><creatorcontrib>Aliramezani, A.</creatorcontrib><creatorcontrib>Yaseri, M.</creatorcontrib><creatorcontrib>Mesdaghinia, A.</creatorcontrib><creatorcontrib>Douraghi, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of applied microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baghani, A.</au><au>Ghourchian, S.</au><au>Aliramezani, A.</au><au>Yaseri, M.</au><au>Mesdaghinia, A.</au><au>Douraghi, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients</atitle><jtitle>Journal of applied microbiology</jtitle><addtitle>J Appl Microbiol</addtitle><date>2018-11</date><risdate>2018</risdate><volume>125</volume><issue>5</issue><spage>1518</spage><epage>1525</epage><pages>1518-1525</pages><issn>1364-5072</issn><eissn>1365-2672</eissn><abstract>Aims
Little is known about the resistance rate and susceptibility profile of Clostridium difficile isolates in Iran. Therefore, the aim of present study is to assess the rate of drug‐resistant C. difficile.
Methods and Results
During a 6‐year period, four hospitals submitted 735 stool specimens from patients suspected for C. difficile infections to the anaerobic bacteriology laboratory. The 46 C. difficile isolates were subjected to disc diffusion and minimum inhibitory concentration (MIC) Test Strips. All isolates were susceptible to vancomycin (VAN) while the highly resistant phenotypes of metronidazole (MTZ) (67·4%), moxifloxacin (78·3%), ciprofloxacin (69·5%) and tetracycline (82·6%) were observed. Of more concern, 67·3% of C. difficile isolates displayed multidrug‐resistant phenotypes. More than half of the isolates (n = 27, 58·6%) were coresistant to ciprofloxacin and moxifloxacin. The MIC90 of VAN was ≤2 mg l−1, whereas this value for MTZ, ciprofloxacin, moxifloxacin and tetracycline was higher than the resistance breakpoints. According to the comparison of interpretive categories for two tests, the categorical agreement was less than 90% for VAN, ciprofloxacin and tetracycline.
Conclusions
The disc diffusion method can be used to detect the isolates with reduced susceptibility to MTZ or moxifloxacin. The high rate of resistance to fluoroquinolones highlights the possibility of the emergence of hypervirulent strains in our settings.
Significance and Impact of the Study
This study provides data regarding the high level of resistance against multiple antibiotics except VAN.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>29957893</pmid><doi>10.1111/jam.14035</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-5861-3182</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1364-5072 |
ispartof | Journal of applied microbiology, 2018-11, Vol.125 (5), p.1518-1525 |
issn | 1364-5072 1365-2672 |
language | eng |
recordid | cdi_proquest_miscellaneous_2062834056 |
source | Alma/SFX Local Collection |
subjects | Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Anti-Infective Agents - pharmacology Antibiotic resistance antibiotic susceptibility testing Antibiotics Bacteria Bacteriology Breakpoints Ciprofloxacin Ciprofloxacin - pharmacology Clostridium difficile Clostridium difficile - drug effects Clostridium difficile - isolation & purification Clostridium difficile - pathogenicity Clostridium Infections - drug therapy Clostridium Infections - microbiology disc diffusion Drug Resistance, Multiple, Bacterial Fluoroquinolones Fluoroquinolones - pharmacology Humans Iran Metronidazole Metronidazole - pharmacology MIC Test Strips Microbial Sensitivity Tests Minimum inhibitory concentration Moxifloxacin Patients Phenotypes resistance Vancomycin Vancomycin - pharmacology |
title | Highly antibiotic‐resistant Clostridium difficile isolates from Iranian patients |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T18%3A22%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Highly%20antibiotic%E2%80%90resistant%20Clostridium%20difficile%20isolates%20from%20Iranian%20patients&rft.jtitle=Journal%20of%20applied%20microbiology&rft.au=Baghani,%20A.&rft.date=2018-11&rft.volume=125&rft.issue=5&rft.spage=1518&rft.epage=1525&rft.pages=1518-1525&rft.issn=1364-5072&rft.eissn=1365-2672&rft_id=info:doi/10.1111/jam.14035&rft_dat=%3Cproquest_cross%3E2120019052%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3535-e6e0485341789e4ca92a0d231bf960a42aa52c764f28fa739c07cf5d233d5c233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2120019052&rft_id=info:pmid/29957893&rfr_iscdi=true |